心肌梗塞后的瓦伦尼克林和心室外皮:一个随机的第二阶段研究
Yunli Shen1, Xiaogang Guo2, Chunyu Zeng3
1State Key Laboratory of Cardiovascular Diseases, Department of Cardiology, and Shanghai Arrhythmia Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
瓦伦尼克林显著降低了后心脏病患者的早发性心室综合体 (PVC) 和心室高心率. 这种针对心脏尼古丁乙胆受体 (nAChRs) 的新方法显示出作为一种安全的抗失律疗法的前景.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统的抗心律失常药物带来了前节律失常的风险.
- 心脏尼古丁性乙胆受体 (nAChRs) 提供了一个新的治疗点.
研究的目的:
- 评估瓦雷尼克林在减少心肌梗塞 (MI) 后早发性心室复合物 (PVC) 的疗效和安全性.
- 评估瓦雷尼克林的生物位参与和抗失常性潜力.
主要方法:
- 一个多中心,随机,双盲,安慰剂控制的第二阶段试验.
- 118名患有频繁PVCs后MI的成年人接受了瓦伦尼克林或安慰剂45天.
- 主要终点:24小时PVC计数的百分比变化;次要终点:响应率和非持续性心室动脉短拍 (VT) 发生率.
主要成果:
- 与安慰剂相比,瓦伦尼克林显著减少了60.1%的PVC负担 (P = 0.001).
- 使用瓦雷尼克林时,观察到更高的响应率 (67.8%vs30.5%) 和更低的非持续静脉瘤发病率 (20.3%vs37.3%).
- 副作用的发生率相似,在瓦雷尼克林组中没有死亡或恶性心室节律失常.
结论:
- 瓦伦尼克林有效地降低了PVC负担和静脉瘤发病率在后心脏病患者没有前节律不良的影响.
- 心脏nAChRs是一个可行的抗不律性标.
- 进一步的大规模结果试验是有必要的,以证实这些发现.
更多相关视频
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
07:56A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts
Published on: February 17, 2023
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome III: Diagnostic Studies
Cardiopulmonary Resuscitation IV: Pharmacological Management
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
